BOSTON--(BUSINESS WIRE)--NeuroMetrix, Inc. (Nasdaq: NURO) reported today that it had shipped its 100,000th Quell® wearable device for treatment of chronic pain since commercial launch in mid-2015. Quell device shipments have posted growth in each of the eight sequential quarters that it has been on the market. Quell has been recognized by numerous awards over the past two years including the SXSW Innovation Award, SBANE Innovation Award, APMA Seal of Approval, and as a finalist for the Best of CES. It has advanced from its commercial introduction at Indiegogo to today’s widespread availability on e-commerce websites, home shopping networks, major retailers and chain drug stores.
“This is a major milestone for the Quell brand,” said Frank McGillin, SVP and Chief Commercial Officer. “We are excited that our patented, 100% drug free technology is making a difference for a growing number of people suffering from chronic pain. There is a building awareness of Quell from media coverage in high profile outlets including Fox 25 News and Bloomberg, as well as our continued investment in TV advertising. Our newest TV ad premiered this week, and highlights how wearable neurotechnology can deliver widespread pain relief. We are pleased with market acceptance of Quell to date and optimistic regarding future growth.”
About Quell
Quell is designed for millions of people suffering from chronic pain. The advanced wearable device is lightweight and can be worn during the day while active, and at night while sleeping. It has been cleared by the FDA for treatment of chronic pain without a prescription. In a recent study, 81% of Quell users reported an improvement in their chronic pain. Quell users can personalize and manage therapy discreetly via the Quell Relief app. Quell also offers advanced health tracking relevant to chronic pain sufferers including pain, sleep, activity, and gait. Quell was the winner of the 2016 SXSW (South by Southwest) Innovation Award for Best Wearable Technology. Quell is available at select healthcare professionals and retailers. Visit QuellRelief.com for more information.
To learn more about NeuroMetrix’s 100,000th Quell device milestone, please visit the LivingQuell blog.
About NeuroMetrix
NeuroMetrix is a commercial stage, innovation driven healthcare company combining neurostimulation and digital medicine to address chronic health conditions including chronic pain, sleep disorders, and diabetes. The company’s lead product is Quell, an over-the-counter wearable therapeutic device for chronic pain. Quell is integrated into a digital health platform that helps patients optimize their therapy and decrease the impact of chronic pain on their quality of life. The company also markets DPNCheck®, a rapid point-of-care test for diabetic neuropathy, which is the most common long-term complication of Type 2 diabetes. The company maintains an active research effort and has several pipeline programs. The company is located in Waltham, Massachusetts and was founded as a spinoff from the Harvard-MIT Division of Health Sciences and Technology in 1996. For more information, please visit www.NeuroMetrix.com.
NeuroMetrix, Inc.
Thomas T. Higgins, 781-314-2761
SVP and Chief Financial Officer
neurometrix.ir@neurometrix.com
